Join the Class Action Against Altimmune
Investors of Altimmune, Inc. have been alerted to an ongoing class action securities lawsuit initiated by Levi & Korsinsky, LLP. Altimmune, known by its stock ticker ALT, has come under scrutiny due to allegations surrounding securities fraud affecting shareholder value.
Class Definition and Timeline
The class action aims to compensate investors who suffered losses between specific dates outlined during the investigation. All affected shareholders are encouraged to seek information regarding their rights and the details of the lawsuit campaign.
Case Background and Allegations
Recently, Altimmune published a press release detailing results from the IMPACT Phase 2b MASH trial concerning their drug Pemvidutide. Unfortunately, the results did not meet the inflated expectations previously set by the company. A significant failure to demonstrate statistical significance regarding primary endpoints resulted in a dramatic decline in the company's stock price.
Impact on Stock Performance
On the day following the announcement—June 26, 2025—Altimmune's stock plummeted from $7.71 to $3.61, marking a staggering 53.2% decrease in just 24 hours. This outcome has raised concerns among investors about the company's transparency and management decisions.
Next Steps for Investors
If you have experienced financial losses with your investment in Altimmune, it is essential to act quickly. Investors have until a specified deadline to petition the court to become lead plaintiffs—a status that may enhance their role in the lawsuit process. Importantly, being a lead plaintiff is not a prerequisite to participate in the recovery process.
No Financial Risk to Participants
Those who join the class action do not need to worry about upfront costs, as participation entails no fees or financial obligations. This factor underscores the accessibility of the legal process and reinforces support for investors seeking justice.
Why Choose Levi & Korsinsky?
Levi & Korsinsky boasts extensive experience in securities litigation, having recovered hundreds of millions of dollars for shareholders over two decades. Their successful track record emphasizes a commitment to advocating for investor rights, making them a trusted choice for representation.
Contact Information
For further inquiries, investors are encouraged to reach out directly to the firm. You can contact Joseph E. Levi, Esq. via email or phone, providing a direct line for guidance through the legal matters pertinent to Altimmune.
Frequently Asked Questions
What is the class action against Altimmune about?
The class action focuses on allegations of securities fraud affecting investors during specific periods and aims to secure compensation for affected shareholders.
What should I do if I lost money on ALT?
Consider joining the class action lawsuit before the upcoming deadline to potentially recover your losses without incurring costs.
Are there any out-of-pocket costs for joining?
No, participating in the class action has no associated fees or financial obligations for shareholders.
Why is Levi & Korsinsky chosen for the case?
The firm has a proven history of successfully advocating for investors and has significant experience in securities litigation.
How can I get in contact with Levi & Korsinsky?
Investors can reach Joseph E. Levi, Esq. via provided contact methods for additional information regarding the lawsuit.
